Source: Virtual Congress 2021 – Deep phenotyping of obstructive diseases for precision medicine



Rating:

Share or cite this content

Citations should be made in the following way:
S. Rønnow (Herlev, Denmark), J. P.M. Blair (Herlev, Denmark), J. M.B. Sand (Herlev, Denmark), B. E. Miller (Washington, United States of America), R. Tal-Singer (Washington, United States of America), J. Vestbo (Manchester, United Kingdom), M. A. Karsdal (Herlev, Denmark), D. J. Leeming (Herlev, Denmark). Identification of distinct trajectories of FEV1 progression in the ECLIPSE cohort. 1285

Member's Comments

No comment yet.

Related content which might interest you: SGRQ-C distribution in the evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) cohort: Characteristics of COPD subjects with extreme score quintiles Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort Source: Eur Respir J 2013; 42: 636-646 Year: 2013 Predicting early vs late vs no re-exacerbation in COPD patients:Analysis of ECLIPSE cohort Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 Determination of COPD characteristics via unsupervised clustering of the ECLIPSE cohort Source: Annual Congress 2011 - Respiratory epidemiology: methods, definitions and phenotypes Year: 2011 Blood biomarkers in COPD: results from the ECLIPSE (evaluation of COPD longitudinally to identify predictive surrogate endpoints) cohort Source: Annual Congress 2009 - Biomarkers, comorbidities and prognosis of COPD Year: 2009 Estimation of a disease progression model for COPD using data from the ECLIPSE study Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 LATE-BREAKING ABSTRACT: Biomarkers of tissue turnover are related to annual change in FEV1 in patients with COPD within the ECLIPSE cohort Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort Source: Eur Respir J, 57 (3) 2001339; 10.1183/13993003.01339-2020 Year: 2021 Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006 Association of testosterone level with phenotypic characteristics and long-term outcomes of men with COPD in the ECLIPSE cohort Source: Annual Congress 2011 - COPD: mechanisms and biomarker Year: 2011 Identification and analysis of clinical phenotypes in COPD patients: PALOMB Cohort Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Longitudinal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Factors associated with prolonged duration of AECOPD:Analysis of the ECLIPSE cohort Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 External validation of two prognostic scores predicting exacerbations in ECLIPSE COPD patients Source: Virtual Congress 2020 – Airflow obstruction, COPD and comorbidities Year: 2020 One-year exacerbation frequency and treatment in the ECLIPSE study cohort Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 Which markers other than FEV1 reflect disease progression in COPD? Source: Eur Respir J 2004; 24: Suppl. 48, 45s Year: 2004 Clinically important results of phenotyping and endotyping of COPD: the ECLIPSE study Source: Annual Congress 2012 - PG14 From phenotypes to endotypes of asthma and COPD Year: 2012 Biomarkers to predict FEV1 decline in smokers and early-onset COPD. Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020 Heterogeneity in the clinical outcomes of COPD: lessons from the ECLIPSE study Source: International Congress 2017 – Heterogeneity in COPD inflammation: implications for therapy and clinical outcomes Year: 2017 Early changes in eDiary COPD symptoms predict trough FEV1 and TDI responders at 12 weeks in the CRYSTAL trial Source: International Congress 2017 – Management of COPD Year: 2017